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Introduction 
 
 Today chronic kidney disease (CKD) is a global health crisis 
creating a huge social and financial burden. More than 10% of the 
worldwide population is affected by CKD and the number of cases is 
constantly increasing. End-stage renal disease (ESRD) is the final 
stage of CKD characterized by complete loss of kidney function. 
Growing incidence of ESRD can be attributed to the rapidly 
escalating incidence of causative disorders, mainly diabetes mellitus 
and hypertension. More than 400 million people suffer from diabetes 
worldwide and diabetic nephropathy (DNP) develops in around one-
third of these cases. Increasing global trends suggest that DNP will 
continue to drive the prevalence of CKD and ESRD in the future. 
 Acute kidney injury (AKI) is also a relevant risk factor for 
the development of CKD that accounts for 2 to 3% of ESRD cases 
annually. However AKI represents a much larger portion of the renal 
disease burden on the long run due to the significantly increased 
long-term risk of CKD and ESRD following AKI, even if renal 
function recovers initially. This relation seems to be bi-directional as 
CKD patients are more vulnerable to AKI as well.  
 For ESRD patients renal replacement therapy (dialysis or 
kidney transplantation) is the sole treatment option. Kidney 
transplantation (KTx) is the preferred treatment as it is associated 
with improved survival and quality of life. Although short-term 
outcomes of KTx have improved substantially due to advances in 
surgical technique and immunosuppression, long-term outcomes 
have remained largely unchanged over the past decades. The factors 
affecting long-term outcome may be either alloantigen-dependent 
(e.g. HLA matching, HLA immunization etc.) or alloantigen-
independent (e.g. donor type and age of both the donor and recipient, 
disease recurrence, time on dialysis). Among alloantigen-
independent factors ischemia/reperfusion injury (IRI) is a major 
complication that has special influence on long-term survival after 
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KTx. IRI is unavoidable and the duration of storage and cold 
ischemia time correlate with delayed graft function.  
Notable morphologic features of ischemic AKI include the 
loss of proximal tubule brush border, depolarization and patchy loss 
of tubular cells and tubular cast formation as well as peritubular 
capillary congestion, endothelial damage and leukocyte 
accumulation. The endothelium of microcirculation plays a pivotal 
role in the pathophysiology of IRI. Even under normal conditions the 
kidney regions housing nephron segments with very high energy 
requirements sustain relative hypoxia due to lower blood flow and 
exchange of oxygen. Relative hypoxia worsens after ischemia, which 
leads to prolonged cellular injury and cell death. Renal blood flow is 
reduced by up to 50%, which persists in the outer medulla even 
during reperfusion. Release of vasoconstrictors such as endothelin is 
enhanced and abundance of vasodilators such as endothelium-
derived nitric oxide (NO) is decreased causing vasoconstriction in 
small arterioles and peritubular capillaries.  
Chronic vasoconstriction is a relevant pathognomic feature of 
DNP as well, where hyperglycemia activates the renin-angiontensin-
aldosterone system (RAAS) leading to ischemia. Renal blood flow is 
decreased due to vasoconstriction, which further activates RAAS and 
increases the production of reactive oxygen species (ROS). These 
processes lead to functional and structural damage of the kidneys.  
Inflammation is also an important contributor both of acute 
and chronic ischemic injury. Cells of the immune system accumulate 
and attach to the endothelium where they release ROS, proteases and 
inflammatory cytokines, all of which aggravate kidney injury in 
acute renal injury models as well as DNP.  
Very recently a new molecule, the Sigma-1 receptor (S1R) 
has become the center of attention in brain ischemia and stroke as a 
possible mediator of key protective mechanisms. S1R is vastly 
expressed in the brain where it is localized in the endoplasmatic 
reticulum (ER), but upon ligand stimulation it translocates to the 
cytosol.  
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In models of brain ischemia S1R agonist treatment reduced infarct 
areas, presumably by promoting cell survival and reducing the 
inflammatory response. S1R stimulation was also effective in 
minimizing infarct size in cardiac hypertrophy. This protection 
seemed to be mediated by the upregulation of protein kinase B (Akt)-
endothelial nitric oxide synthase (eNOS) signaling. 
 These preliminary results in brain and cardiac ischemia 
suggest that S1R activates vasodilatative and protective pathways. 
Therefore it is rather presumable that S1R agonists could trigger 
similar mechanisms in renal IRI. Since renal IRI has high morbidity 
and mortality and treatment options are still very limited better 
understanding of the underlying molecular mechanisms are essential 
for developing novel renoprotective therapies.  
 In our preclinical experiments - during my PhD work - we 
aimed to investigate the promising option of S1R agonist treatment 
in acute and chronic kidney injury.  
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Objectives 
 
The purpose of our experiments was to investigate the 
pathomechanisms of IRI-induced AKI in order to identify new 
therapeutic targets that can be used in KTx as well as in DNP. Based 
on the current literature demonstrating that S1R is protective in brain 
and heart ischemia the main aim was to investigate the effect of S1R 
and its modulation in renal diseases.  
 
Our aims were the following:  
 
1. To investigate the intrarenal and subcellular localization of S1R in 
the normal and ischemic kidney 
 
2. To analyze the molecular mechanism of S1R - mediated effects  
 
3. To determine the possible renoprotective effect of S1R agonism in 
acute (renal IRI) and chronic (DNP) models of kidney disease 
 
4. To evaluate the protective effect of S1R agonist pretreatment in 
KTx 
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Methods 
 
Renal ischemia/reperfusion injury model and treatment groups 
 
Adult, male Wistar rats weighing 200±15g were used in all 
experiments. Renal ischemia was accomplished by cross-clamping 
the left renal pedicles for 50 min. Before the end of the ischemic 
period the contralateral kidney was taken out, the clips were 
removed. Sham animals underwent laparotomy of the same duration 
without clamping. At pre-determined times of reperfusion, blood 
samples were collected, the remnant kidneys were harvested. 
To test the effect of dehydroepiandrosterone (DHEA) rats were 
pretreated first 25 hours, then 1 hour before the surgical procedure 
with:  
(i) isotonic saline as vehicle  
(ii) DHEA (4 mg/bwkg)  
To investigate the effect of fluvoxamine (FLU) animals were treated 
30 min prior to the ischemic insult as follows:  
(i) isotonic saline as vehicle 
(ii) FLU (20 mg/bwkg) 
(iii) FLU (20 mg/bwkg) and NE100 (1 mg/bwkg)  
To test the NO-mediated effect the following pretreatment was 
applied 30 min prior to the ischemic insult:  
(i) FLU (20 mg/bwkg) and L-NAME (10 mg/bwkg, non-
selective NOS inhibitor)  
(ii) FLU (20 mg/bwkg) and L-NIO (20 mg/bwkg, selective 
eNOS inhibitor) 
(iii) FLU (20 mg/bwkg) and  7-NI (25 mg/bwkg, selective 
nNOS inhibitor) 
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Figure 1. Experimental design of renal IRI 
 
Rat model of kidney isograft autotransplantation  
 
 Kidneys were perfused with cold Custodiol perfusion 
solution, then removed from the animal: kidneys were placed into a 
container for 2 hours filled with: 
(i) cold Custodiol perfusion solution  
(ii) cold Custodiol perfusion solution containing 0.003 
mg/mL FLU   
After 2 hours kidneys were placed back into the rats and end-to-end 
anastomoses of the renal artery, vein and ureter were performed. 
Contralateral kidneys were removed. Total warm ischemia time was 
35 min.  
 
Figure 2. Experimental design of renal autotransplantation 
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Rat model of type 1 diabetes mellitus (DM1) and experimental 
groups 
 
DM1 was induced by a single intraperitoneal injection of 65 
mg/bwkg streptozotocin (STZ) in freshly prepared 0.1 M citrate 
buffer. DM1 rats were randomly divided into four groups and were 
treated by oral gavage daily at 10:00 AM as follows:  
(i) 20 mg/bwkg FLU for 7 weeks 
(ii) 20 mg/bwkg FLU for 2 weeks after 5 weeks of DM1 
(iii) 2 mg/bwkg FLU for 2 weeks after 5 weeks of DM1  
Age-matched, non-diabetic control rats were treated per os with 
saline daily at the same time as the diabetic animals. 
 
Figure 3. Experimental design of type 1 diabetes mellitus 
 
In vitro model 
 
 All in vitro experiments were performed on human proximal 
tubular epithelial cell line (HK2). Oxidative stress was induced by 
400 µM hydrogen-peroxide treatment for 30 min. Cells were treated 
30 min prior to harvest as follows:  
(i) FLU (10 µM)  
(ii) FLU (10 µM) + NE100 (3 µM) 
(iii) FLU (10 µM)  + AktVIII inhibitor (10 µM) 
(iv) FLU (10 µM)  + AktIV inhibitor (10 µM)   
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Experiments  
 
Renal functional and metabolic parameters 
The following renal functional and metabolic parameters were 
measured: serum creatinine (SCr), BUN, serum AST, serum glucose, 
fructosamine, electrolytes (sodium, potassium, chloride), albumin, 
total protein, triglycerides, total cholesterol and glutamate-pyruvate 
transaminase. 
 
Histology 
 Tubular injury was evaluated on hematoxylin-eosin and 
periodic acid-Schiff stained kidney sections.  
Masson’s trichrome staining was used to evaluate tubulointerstitial 
fibrosis and Sirius red staining to evaluate collagen accumulation. 
S1R localization was determined with S1R-specific DAB staining 
and fluorescent immunohistochemistry.  
 
In vivo measurement of renal perfusion and structure 
 Two-photon microscopy was used to assess renal injury and 
to measure peritubular capillary diameters in living rats.   
 
Protein abundance measurements 
 Western blot was used to measure the followin proteins:  
S1R, phospho-Akt (Ser473), phospho-eNOS (Ser1177) and nNOS. 
Bands of interest were factored for Ponceau red staining to correct 
for any variations in total protein loading. 
 
Measurement of tubular injury markers mRNA 
 Kidney injury markers Hif-1α, Ngal, Kim-1 and Mcp-1 were 
measured using quantitative real-time PCR and normalized against 
Gapdh as a housekeeping gene.  
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NO measurement 
The total stable oxidation products of NO metabolism 
(NO2/NO3) of serum and HK2 cell homogenates were assessed using 
Griess reagent. 
 
S1R gene silencing 
HK2 cells were transfected with S1R specific siRNA or 
negative control siRNA using Lipofectamine 2000. The efficacy of 
knockdown was determined by Western blot. 
 
Statistical analysis  
Parametrical data are expressed as means ± SEM, while non-
parametrical data as median ± range. Statistical analyzes were 
performed using Prism software (version 5.00; GraphPad Prism 
Software). Survival studies were assessed by Logrank test. Multiple 
comparisons and possible interactions were evaluated by one-way 
ANOVA followed by Bonferroni post-hoc test. For non-parametrical 
data the Kruskal–Wallis ANOVA on ranks followed by Fischer 
exacts test was used. P values of <0.05 were considered significant. 
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Results  
 
Sigma-1 receptor is expressed in the kidney 
 
Our group is the first to describe the region-specific 
distribution of Sigma-1 receptor (S1R) expression in the kidney. 
S1R-specific DAB staining and Western blot revealed that S1R 
expression was most prominent in the renal cortex, but was also 
present in the medulla and papilla. Co-staining with proximal tubular 
brush border-specific PAS and anti-S1R DAB revealed that S1R is 
definitely expressed in proximal tubules but not in glomeruli. S1R 
fluorescent immunohistochemistry double staining with S1R and 
antibodies specific to different nephron segments supported the 
finding that S1R is mainly present in proximal tubules: S1R was co-
localized with proximal tubule-specific gamma-glutamyltransferase, 
but not with Na+/K+-ATP-ase in distal tubules, eNOS in glomeruli or 
neuronal NOS (nNOS) in the macula densa. 
 
DHEA improves post-ischemic kidney function and ameliorates 
structural injury  
 
 After confirming the presence of S1R in the kidney our goal 
was to investigate the effect of S1R agonist treatment on renal IRI. 
DHEA is a highly abundant steroid hormone, which is also an 
endogenous agonist of S1R. 
 Post-ischemic survival was followed and compared to sham-
operated controls for seven days. DHEA-pretreated rats survived 
longer than vehicle-treated ones (median survival: 72 versus 36 
hours, P<0.001). 
 Another series of animals were sacrificed after 24 hours of 
reperfusion to investigate the acute effects of IRI. Intravital two-
photon microscopy allowed us to measure changes of peritubular 
capillary diameters in live rats. Post-ischemic vasoconstriction was 
apparent suggesting that the subsequent decline in renal blood flow 
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could be a causative factor of renal functional and structural damage. 
DHEA pretreatment improved kidney function and prevented 
peritubular vasoconstriction.  
 Histologic changes were consistent with functional decline: 
brush borders disappeared, the majority of tubules showed cell 
necrosis and extensive cast formation. DHEA pretreatment 
considerably reduced tubular necrosis and partly preserved brush 
borders.  
 
High affinity S1R agonist FLU is renoprotective following kidney 
IRI 
 
To substantiate the crucial role of S1R in IRI, in a second set 
of experiments rats were pretreated with FLU that has much higher 
affinity to S1R than DHEA. 
FLU-treated rats survived significantly longer than vehicle or 
FLU+NE100 (selective S1R antagonist)-treated ones (median 
survival: 67 versus 36 and 49 hours respectively, P<0.001).  
SCr, BUN and serum AST were less elevated in FLU-treated 
rats after 24 hours of reperfusion and the improvement was 
neutralized by NE100 suggesting that S1R agonism successfully 
diminishes acute renal injury. Ngal and Kim-1 are specific, early 
indicators of tubular injury. Increased mRNA expression of these 
markers was ameliorated by FLU suggesting milder proximal tubular 
injury.   
 
FLU ameliorates renal structural damage 
 
 IRI-induced histologic injury was assessed on PAS-stained 
kidney sections as well as in vivo using two-photon microscopy. 
Severe structural damage was apparent in ischemic kidneys: 
leukocyte infiltration, hyaline accumulation and necrotic tubules 
were prevalent as well as loss of brush border indicating loss of 
reabsorption capacity. On the other hand tubular damage and cell 
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necrosis were only moderate, and brush borders were intact in 
several regions of FLU-treated kidneys after 24 hours of reperfusion. 
 
The role of S1R in proximal tubular cells 
 
 To our best knowledge our group is the first to show that S1R 
is expressed in human proximal tubular cells. S1R abundance 
remained unchanged after FLU or H2O2 treatment; however 
localization was different under normal conditions and oxidative 
stress. The receptor showed perinuclear localization in control cells, 
but was detected everywhere in the cytosol and also in nuclei after 
H2O2 or FLU treatment. 
 
FLU induces S1R-mediated NO production in HK2 cells 
 
 A possible signaling pathway by which vasodilatative NO 
could be produced is the Akt-eNOS pathway. FLU increased 
phospho-eNOS (peNOS, Ser1177; the active form of the eNOS 
enzyme) protein levels in HK2 cells both under normal conditions 
and oxidative stress. Parallel with successful S1R gene silencing 
peNOS protein was lower compared to scrambled siRNA-treated 
negative control cells. Decreased peNOS production in FLU-treated 
S1R gene silenced cells verified the regulatory role of S1R in peNOS 
expression. To confirm the role of Akt in FLU-induced NOS 
activation and NO production, both upstream (Akt IV) and 
downstream (Akt VIII) Akt inhibitors were used. Inhibition of Akt 
suppressed peNOS and subsequently NO production in FLU-treated 
cells. 
 
S1R-mediated renal vasoregulation in SHAM-operated rats 
 
Once the role of S1R in NO production was characterized 
under in vitro circumstances the next step was to investigate the 
vasoregulatory effect of FLU in the rat kidney. Intravital two-photon 
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microscopy was used to measure peritubular capillary diameters in 
SHAM-operated rats after 30 minutes of FLU treatment. Parallel 
with increased peNOS and NO production FLU pretreatment caused 
peritubular capillary dilatation.  
Peritubular capillaries showed significant vasoconstriction 
after 24 hours of reperfusion. Parallel with increased nitrite 
production capillary dilatation was significant in FLU-treated rats 
after 24 hours of reperfusion as well, which was diminished by 
NE100 or various NOS inhibitors supporting that the vasodilative 
effect of FLU is S1R-mediated and NOS-dependent. 
 
The S1R - Akt - NOS signaling pathway in the kidney 
 
 FLU increased pAkt (Ser473) and peNOS (Ser1177) protein 
abundance as soon as 30 minutes after treatment, whereas S1R and 
nNOS remained unchanged. On the other hand after 24 hours of 
reperfusion all measured proteins were increased especially in FLU-
treated rats. These results indicate that S1R signaling is instantly 
activated by FLU and is rapidly followed by peNOS production, but 
nNOS generation only increases later during reperfusion. As a result 
of increased NOS abundance NO production was also considerably 
increased contributing to vasodilatation in the post-ischemic kidney. 
 
The effect of FLU-treatment on the transplanted kidney 
 
Kidney function was substantially improved in FLU-treated 
rats as shown by decreased SCr and AST levels, however BUN was 
not decreased at this early time point yet. Early markers of kidney 
injury Ngal, Kim-1 and Mcp-1 were also significantly less elevated 
in FLU-treated, transplanted kidneys. 
PAS-stained sections of FLU-treated kidneys showed milder 
histological damage. Glomeruli were intact, tubular nuclei and 
plasma showed normal staining. Tubular brush borders were 
preserved. Similarly, structure was better preserved in kidneys that 
 15 
were perfused with FLU, but harvested after 2 hours of cold 
ischemia. 
 
Chronic FLU-treatment is protective in DNP 
 
DM1 induced severe renal impairment with increased SCr 
and BUN values. Fractional sodium excretion (FeNa) (reflecting 
tubular function) was increased and significant albuminuria 
(representing mainly glomerular function) were present indicating 
the development of DNP. Both long- and short-term treatment with 
FLU remarkably improved renal functional parameters. 
FLU decreased DM1-induced mesangial matrix expansion in 
long-term, as well as short-term treatment in both dosages. 
Fibrotic areas were extensive in DM1 kidneys. Both long- 
and short-term treatment with FLU successfully reduced 
tubulointerstitial fibrosis. 
 The amount of extracellular matrix was doubled in DM1 
kidneys compared to controls, but was significantly reduced after 
long-term FLU treatment. Short-term FLU treatment did not reduce 
collagen production. 
 Changes in the S1R-Akt-eNOS signaling pathway were 
evaluated after long- and short-term FLU treatment. There was an 
increasing tendency in S1R and pAkt protein levels, however did not 
reach the level of significance (p=0.06). On the other hand depressed 
peNOS production in DM was rescued by both long- and short-term 
FLU treatment. 
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Conclusions 
 
1. We were the first to clarify that S1R is expressed in different 
nephron segments, predominantly in the cortex, but also in 
the medulla and papilla. 
 
2. Our in vivo and in vitro experiments revealed that upon 
stimulation S1R translocates from the mitochondria-
associated ER to the cytoplasm and nucleus. 
 
3. We showed that treatment with endogenous S1R agonist 
DHEA is renoprotective in a rat model of IRI. 
 
4. We demonstrated that exogenous, high-affinity S1R agonist 
FLU treatment is protective in renal IRI. It substantially 
improves post-ischemic survival, ameliorates functional and 
structural kidney damage, as well as inflammation. 
 
5. We described the role of S1R in improving perfusion in the 
post-ischemic kidney by inducing Akt-NOS signaling and 
NO production.  
 
6. We demonstrated the renoprotective effect of FLU treatment 
in KTx. 
 
7. We showed that chronic FLU treatment ameliorates 
functional and structural kidney damage in diabetic 
nephropathy, presumably via hindering fibrosis and rescuing 
eNOS production. 
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